Comparison of clinical outcomes of MIC patients to outcomes of matched controls
opportunistic infections, opportunistic pneumonia
KIDNEY, OPPORTUNISTIC INFECTIONS, COMPLICATIONS
This is the 5-year follow up of 10 patients who participated in a phase I clinical trial of donor-derived MIC therapy for individualized immunosuppression in living donor kidney transplant recipients (TOL-1 Study, Overall graft survival in MIC patients was not significantly different from survival in transplanted controls (log rank Survival rates in MIC patients compared to transplanted controls. Kidney function and integrity in MIC patients compared to transplanted controls. Serum creatinine During follow up to year 5, no acute rejection episodes were noted in MIC patients and transplanted controls (Outcomes and complications in MIC patients compared to transplanted controls out to year 5.
One MIC patient was retrospectively found to have mild CMV reactivation 5 months after surgery, which resolved without further treatment (patient R1 of group A). Otherwise, no opportunistic infections were detected in the MIC patients during rigorous screening. In comparison, 8 transplanted controls (53%) developed opportunistic infections during follow up including 4 episodes of opportunistic pneumonia and 6 episodes of CMV- or BKV-replication (log rank When only 10 of the 15 patients who had no formal contraindication to enrollment in the TOL-1 Study (N = 3) or were excluded during screening (N = 2) were analyzed, virtually the same results were obtained (